Back HIV/AIDS HIV/AIDS Topics HIV Testing & Diagnosis BHIVA 2016: First Data on Uptake of HIV Self-Testing in the U.K.

BHIVA 2016: First Data on Uptake of HIV Self-Testing in the U.K.


Between April 2015 and February 2016, almost 28,000 people have paid £29.95 (about US$45) for a kit allowing them to test for HIV at home, according to a presentation at the recent British HIV Association (BHIVA) conference in Manchester. Marketing on Grindr has been important in driving sales, which have been concentrated in non-urban areas.

[Produced in collaboration with]

While both are often promoted as "home testing" for HIV, it’s important to distinguish between self-sampling kits and self-testing kits.

Self-sampling involves the user collecting their own sample and sending it to a laboratory for analysis. Several self-sampling schemes have been promoted by health bodies in recent years, including by Test.HIV and the Terrence Higgins Trust.

In contrast, self-testing involves the user performing the whole test themselves -- collecting the sample and interpreting the test result. Last April, a commercial company, BioSure, obtained regulatory approval and marketed the U.K.’s first HIV self-testing kit. Whereas several self-sampling schemes are provided free of charge to the end user, the self-test is currently only available for purchase through online retailers. It may soon also be available at some high-street chemists.

A rival manufacturer, OraSure, has also obtained European regulatory approval for a self-testing kit, but have not yet made it commercially available in Europe. OraSure appears to be concentrating on the American market for the moment.

Three-quarters of BioSure’s 27,917 sales have been to men. The most successful form of marketing has been promotion on the gay dating app Grindr, with sales typically quadrupling after Grindr ads. Sales were also high during HIV Testing Week and on World AIDS Day, but the greatest peak was following Charlie Sheen’s disclosure of his HIV status.

Three-quarters of test kit sales have been to people living outside large cities. Half of those purchasing the test say that they have never tested for HIV before.

These patterns of demand and uptake are broadly similar to those of HIV self-sampling kits. But whereas self-sampling schemes are able to report the number of HIV-positive results of people testing, people self-testing do not need to report their results to anyone. Anecdotally, people getting a reactive or positive result with a self-testing kit often use a variety of other HIV testing services, including community services, in order to confirm the result.

BioSure says that the number of false reactive results reported to them (6 cases) is far lower than they expected, and represents 0.02% of tests purchased. In addition, 12 people (0.004%) reported having an invalid test -- meaning that they were not able to complete the test and read a result.

User feedback has been positive, with 97% saying that they would use the test again and 98% saying that the test was easy to perform. Users appeared to find the test discreet, simple, and convenient.

In a plenary session, Alison Rodger and Michael Brady said that HIV self-testing might increase rates of HIV testing by removing social and structural barriers, including the time required and geographical distance from testing facilities, particularly for people living in rural areas. Self-testing appears to be attractive to people who particularly value privacy, confidentiality, and autonomy. It may facilitate the more frequent HIV testing which is required for harm reduction approaches such as serosorting, disclosure of HIV status, and pre-exposure prophylaxis (PrEP).

But HIV self-testing may involve harms as well as benefits. A particular concern is whether people getting a reactive result will approach health services for confirmatory testing and will be effectively linked to medical care. We do not know if some people receiving a reactive result without professional support being immediately available will have particular difficulty dealing with the news. Further, tests could be used coercively.

Self-tests are not available for bacterial sexually transmitted infections, so there could be a delay in diagnosing these if people do not visit medical providers for HIV Tests. HIV self-tests are second-generation tests, and therefore have a much longer window period than the fourth-generation tests which are used in sexual health clinics. This means that recent HIV infections can easily be missed, and this could be a particular problem if self-tests are used by high-risk populations and are relied upon to make decisions about condom use.

As it is unknown whether the benefits outweigh the potential harms, a large randomized controlled trial called Pantheon will begin soon. It aims to find out whether making HIV self-testing readily available increases the rate of HIV diagnosis, the frequency of HIV testing, and the number of gay men who test. The study will also examine the impact of self-testing -- and other prevention interventions -- on sexual behavior.

This UK study is being conducted with gay men. There are very few data and very few studies on HIV self-testing in other groups in high-income countries.



M Brady. Self-testing for HIV: initial experience of the UK's first kit. 22nd Annual Conference of the British HIV Association(BHIVA 2016). Manchester, April 19-22, 2016. Abstract O19.


A Rodger and M Brady. DIY Testing. 22nd Annual Conference of the British HIV Association(BHIVA 2016). Manchester, April 19-22, 2016.